How the FDA Regulates Peptides
The FDA regulates peptide therapies through the same framework it uses for all drugs and biological products. When a pharmaceutical company develops a new peptide drug, it must go through the full drug approval process - preclinical testing, Phase 1-3 clinical trials, and New Drug Application (NDA) or Biologics License Application (BLA) review. This process typically takes 10-15 years and costs hundreds of millions of dollars. Peptides that complete this process receive FDA approval for specific indications with defined dosing, contraindications, and labeling.
Several peptide therapies have received full FDA approval. Semaglutide is approved for type 2 diabetes and chronic weight management. Tirzepatide is approved for type 2 diabetes and weight management. Bremelanotide (PT-141) is approved for hypoactive sexual desire disorder. Tesamorelin is approved for HIV-associated lipodystrophy. These approved peptides have the most comprehensive safety and efficacy data available.
Many peptides used in clinical practice have not individually gone through the FDA approval process - not because they are unsafe, but because the approval process is designed for pharmaceutical companies seeking commercial exclusivity. Natural peptides and established compounds are often not commercially viable for the approval process. These peptides are available through compounding pharmacies under a separate regulatory framework.
Compounding Pharmacy Regulations
Compounding pharmacies operate under a specific regulatory framework that allows them to prepare customized medications, including peptides, under the supervision of a pharmacist. There are two primary regulatory categories for compounding pharmacies under the Federal Food, Drug, and Cosmetic Act.
Section 503A pharmacies prepare compounded medications in response to individual patient prescriptions from licensed physicians. These pharmacies are primarily regulated by state boards of pharmacy and must meet state-specific quality standards. They compound medications on a patient-by-patient basis and cannot distribute products across state lines without state-level agreements.
Section 503B pharmacies - also called outsourcing facilities - are registered with and inspected by the FDA. They follow current Good Manufacturing Practices (cGMP), conduct sterility and potency testing, and can distribute compounded products in larger quantities. These facilities undergo regular FDA inspections and are held to higher manufacturing standards than 503A pharmacies. GetPepWell partners with pharmacies that meet or exceed these regulatory standards to ensure our patients receive safe, accurately dosed medications.
Understanding Peptide Regulatory Categories
Peptides used in clinical practice fall into several regulatory categories that patients should understand. FDA-approved peptides have completed the full approval process and have defined labeling, approved indications, and post-market surveillance. These represent the highest level of regulatory oversight and evidence support.
Compounded peptides are prepared by licensed pharmacies using bulk pharmaceutical ingredients. When a peptide is available as an FDA-approved product, compounding pharmacies can prepare compounded versions under certain conditions - typically when there are documented shortages or when the compounded version offers a clinically meaningful difference (such as a different dosage form or strength). The regulatory landscape around compounding of commercially available products is complex and evolving.
Some peptides exist in a category where they have substantial research support and clinical use history but have not gone through the formal FDA approval process for any specific indication. BPC-157, certain growth hormone secretagogues, and thymosin alpha-1 (approved in other countries but not the US) fall into this category. These peptides are available through compounding pharmacies and can be prescribed by physicians exercising their clinical judgment, but patients should understand that the evidence base differs from FDA-approved products.
Recent Regulatory Developments
The regulatory landscape for peptides has been evolving significantly. The FDA has been reviewing its approach to compounded peptides, particularly regarding which bulk drug substances can be used in compounding. The agency maintains a list of substances that can be used in compounding (the "bulks" list) and has been evaluating specific peptides for inclusion or exclusion from this list.
These regulatory changes affect the availability of certain compounded peptides. When the FDA determines that a peptide should not be on the bulks list, compounding pharmacies may no longer be able to prepare it. Conversely, inclusion on the bulks list confirms that a substance can be compounded under the appropriate regulatory framework. Patients should be aware that the availability of specific compounded peptides may change as regulatory reviews are completed.
GetPepWell stays current with all regulatory developments and adjusts our product offerings accordingly. If a regulatory change affects a peptide you are currently using, your physician will proactively contact you to discuss alternative treatment options. We only offer peptides that are legally available through properly licensed compounding pharmacies in full compliance with current federal and state regulations.
What This Means for Patients
Understanding the regulatory framework helps patients make informed decisions about peptide therapy. When your physician recommends a specific peptide, ask about its regulatory status - is it FDA-approved for your indication, FDA-approved for a different indication (off-label use), or a compounded product? Each category carries different levels of evidence and oversight, and understanding where your treatment falls helps you participate meaningfully in treatment decisions.
Patients should know their rights and protections. You have the right to know which pharmacy is preparing your medication, to receive information about the peptide's regulatory status, to understand the evidence supporting its use, and to be informed of any regulatory changes that affect your treatment. A responsible provider like GetPepWell proactively shares this information without patients having to request it.
The most important protection patients have is working with a licensed physician who prescribes based on clinical evidence and medical judgment, and a licensed pharmacy that compounds under regulatory oversight. This combination of medical expertise and pharmaceutical quality control provides a safety framework that unregulated peptide sales simply cannot match. If a provider or supplier cannot clearly explain the regulatory basis for the products they offer, that is a significant red flag.
Avoiding Unregulated Products
The growth of interest in peptide therapy has unfortunately led to a proliferation of unregulated peptide products sold online, often marketed as "research chemicals" or "for research purposes only." These products are not manufactured under pharmaceutical standards, not tested for human safety, and not subject to any regulatory oversight. Independent testing of grey-market peptides has repeatedly found contamination, incorrect potency, and even entirely wrong compounds.
Red flags that indicate an unregulated peptide source include: no prescription required, products labeled "not for human consumption" or "for research only," no pharmacy license displayed, prices significantly below market rates, no physician consultation offered, products shipped from overseas without proper import controls, and payment accepted only via cryptocurrency or wire transfer.
Legitimate peptide therapy always involves a licensed physician consultation, a valid prescription, and dispensing from a licensed pharmacy. At GetPepWell, every step of the process - from medical evaluation to prescription to pharmacy fulfillment - occurs within the regulated healthcare system. This is not a marketing distinction; it is a fundamental safety requirement. Patients who obtain peptides outside this framework accept significant and unnecessary health risks.